Zinc acetate anhydrous
As of the edition of 20 October 2026, Zinc acetate anhydrous is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Depinar
- First approved
- 1 January 1982 (US)
- Approvals on record
- 9 in 3 regions
- Holder of the most recent approval
- Nobelpharma; 4 holders in all
- Registered trials
- 11, 0 stopped early
- Disease areas
- Digestive system; Inherited and neonatal; Nervous system; Lungs and airways; Mouth and teeth; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 6 | 6 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Teva | Earlier holder | 1997 to now |
| Nobelpharma | Applicant and Lead sponsor of trials | 2004 to now |
| B. Braun Medical | Applicant | 2017 to now |
| Eton Pharmaceuticals | Acquired holder | 2025 to now |